New drugs for the treatment of myelofibrosis

Current Hematologic Malignancy Reports

Volumn 5, Issue 1, 2010, Pages 15-21

  Mesa, Ruben A ^a  

^a MAYO CLINIC   (United States)

Author keywords

JAK2; Myelofibrosis; Myeloproliferative disorder

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BUSULFAN; CLADRIBINE; CYT 387; DANAZOL; ERYTHROPOIETIN; GIVINOSTAT; HYDROXYUREA; IMMUNOMODULATING AGENT; INCB 018424; LBH 539; LENALIDOMIDE; LESTAURTINIB; LY 2784544; MELPHALAN; NANDROLONE; OXYMETHOLONE; PHOSPHORUS 32; PLACEBO; POMALIDOMIDE; SB 1518; STEROID; TG 101348; THALIDOMIDE; UNCLASSIFIED DRUG; XL 019;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ARTHRALGIA; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG TOLERABILITY; EDEMA; ERYTHROCYTE TRANSFUSION; GASTROINTESTINAL SYMPTOM; HIRSUTISM; HUMAN; HYPERTENSION; LEG ULCER; LEUKEMIA; LIVER ADENOMA; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELOFIBROSIS; MYELOID METAPLASIA; NEUROPATHY; NEUROTOXICITY; PALLIATIVE THERAPY; POLYCYTHEMIA VERA; PROSTATE CANCER; REVIEW; SEDATION; SIDE EFFECT; SPLENOMEGALY; THROMBOCYTHEMIA; THROMBOCYTOPENIA; THROMBOCYTOSIS; THROMBOSIS;

ANEMIA; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DNA METHYLATION; DRUGS, INVESTIGATIONAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC FACTORS; JANUS KINASE 2; PALLIATIVE CARE; PRIMARY MYELOFIBROSIS; PROTEIN KINASE INHIBITORS; SPLENOMEGALY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 76649136120     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-009-0037-y     Document Type: Review

References (54)

1. A Tefferi J Thiele A Orazi, et al. 2007 Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel Blood 110 1092 1097 10.1182/blood-2007-04- 083501 1:CAS:528:DC%2BD2sXptFKmurg%3D 17488875 (Pubitemid 47281402)
2. RA Mesa J Niblack M Wadleigh, et al. 2007 The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international internet-based survey of 1179 MPD patients Cancer 109 68 76 10.1002/cncr.22365 17123268 (Pubitemid 46120195)
3. RA Mesa CY Li RP Ketterling, et al. 2005 Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases Blood 105 973 977 10.1182/blood-2004-07-2864 1:CAS:528: DC%2BD2MXhtFCgsLg%3D 15388582 (Pubitemid 40170863)
4. F Cervantes B Dupriez A Pereira, et al. 2009 This key reference for the prognosis of patients with primary myelofibrosis is the most definitive prognostic paper to date, drawing on experience with over 1000 patients Blood 113 2985 2901 10.1182/blood-2008-07-170449
5. JT Reilly 1997 Idiopathic myelofibrosis: pathogenesis, natural history and management Blood Rev 11 233 242 10.1016/S0268-960X(97)90022-9 1:STN:280:DyaK1c7kt1Cmsw%3D%3D 9481452 (Pubitemid 28045207)
6. CA Koch CY Li RA Mesa A Tefferi 2003 Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment Mayo Clin Proc 78 1223 1233 10.4065/78.10.1223 14531481
7. BR Anger E Seifried J Scheppach H Heimpel 1989 Budd-Chiari syndrome and thrombosis of other abdominal vessels in the chronic myeloproliferative diseases Klin Wochenschr 67 818 825 10.1007/BF01725198 1:STN:280:DyaK3c%2FhtlWnsA%3D%3D 2796252
8. HJ Deeg TA Gooley ME Flowers, et al. 2003 Allogeneic hematopoietic stem cell transplantation for myelofibrosis Blood 102 3912 3918 10.1182/blood-2003- 06-1856 1:CAS:528:DC%2BD3sXpsFamurY%3D 12920019 (Pubitemid 37486970)
9. D Rondelli G Barosi A Bacigalupo, et al. 2005 Allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia Blood 1-5 4115 4119 10.1182/blood-2004-11-4299 (Pubitemid 40656163)
10. Kroger N, Holler E, Kobbe G, et al.: Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood 2009 Oct 7 (Epub ahead of print).
11. JN Rodriguez ML Martino JC Dieguez D Prados 1998 rHuEpo for the treatment of anemia in myelofibrosis with myeloid metaplasia. Experience in 6 patients and meta-analytical approach Haematologica 83 616 621 1:CAS:528: DyaK1cXmsVCls7k%3D 9718866
12. EC Besa PC Nowell NL Geller FH Gardner 1982 Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: the value of chromosomal studies in predicting response and survival Cancer 49 308 313 10.1002/1097-0142(19820115)49:2<308::AID-CNCR2820490217>3.0.CO;2-4 1:STN:280:DyaL38%2FptlSquw%3D%3D 7053830
13. F Cervantes JC Hernandez-Boluda A Alvarez, et al. 2000 Danazol treatment of idiopathic myelofibrosis with severe anemia Haematologica 85 595 599 1:CAS:528:DC%2BD3cXmsVGgsrc%3D 10870115
14. V Levy A Bourgarit A Delmer, et al. 1996 Treatment of agnogenic myeloid metaplasia with danazol: a report of four cases Am J Hematol 53 239 241 10.1002/(SICI)1096-8652(199612)53:4<239::AID-AJH5>3.0.CO;2-Z 1:CAS:528:DyaK2sXks1GitQ%3D%3D 8948661 (Pubitemid 26419710)
15. E Lofvenberg A Wahlin 1988 Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea Eur J Haematol 41 375 381 1:STN:280:DyaL1M%2FmsFSnug%3D%3D 3197824
16. MC Petti R Latagliata T Spadea, et al. 2002 Melphalan treatment in patients with myelofibrosis with myeloid metaplasia Br J Haematol 116 576 581 10.1046/j.0007-1048.2001.03331.x 1:CAS:528:DC%2BD38XislSns7s%3D 11849213 (Pubitemid 34178656)
17. LN Faoro A Tefferi RA Mesa 2005 Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia Eur J Haematol 74 117 120 10.1111/j.1600-0609.2004.00370.x 1:CAS:528: DC%2BD2MXitVGnsL0%3D 15654901 (Pubitemid 40175314)
18. A Tefferi MA Elliott 2000 Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia [letter] Blood 96 4007 1:CAS:528:DC%2BD3cXosVGms78%3D 11186278
19. L Canepa F Ballerini R Varaldo, et al. 2001 Thalidomide in agnogenic and secondary myelofibrosis Br J Haematol 115 313 315 10.1046/j.1365-2141.2001. 03072.x 1:CAS:528:DC%2BD3MXptVyqsrY%3D 11703326 (Pubitemid 34203493)
20. G Barosi A Grossi B Comotti, et al. 2001 Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia Br J Haematol 114 78 83 10.1046/j.1365-2141.2001.02918.x 1:CAS:528:DC%2BD3MXmtVyisr8%3D 11472348 (Pubitemid 32702636)
21. M Merup J Kutti G Birgergard, et al. 2002 Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia Med Oncol 19 79 86 10.1385/MO:19:2:79 1:CAS:528:DC%2BD38XmtF2iu7k%3D 12180484 (Pubitemid 34625929)
22. MA Elliott RA Mesa CY Li, et al. 2002 Thalidomide treatment in myelofibrosis with myeloid metaplasia Br J Haematol 117 288 296 10.1046/j.1365-2141.2002.03443.x 1:CAS:528:DC%2BD38XkvVGltbY%3D 11972510 (Pubitemid 34451143)
23. RA Mesa DP Steensma A Pardanani, et al. 2003 A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia Blood 101 2534 2541 10.1182/blood-2002-09- 2928 1:CAS:528:DC%2BD3sXivVWgur4%3D 12517815 (Pubitemid 36857609)
24. A Tefferi J Cortes S Verstovsek, et al. 2006 Lenalidomide therapy in myelofibrosis with myeloid metaplasia Blood 108 1158 1164 10.1182/blood-2006-02- 004572 1:CAS:528:DC%2BD28Xot1ymtL0%3D 16609064 (Pubitemid 44232010)
25. A List S Kurtin DJ Roe, et al. 2005 Efficacy of lenalidomide in myelodysplastic syndromes N Engl J Med 352 549 557 10.1056/NEJMoa041668 1:CAS:528:DC%2BD2MXhtFemsrc%3D 15703420 (Pubitemid 40204668)
26. A Tefferi TL Lasho RA Mesa, et al. 2007 Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions Leukemia 21 1827 1828 10.1038/sj.leu.2404711 1:CAS:528: DC%2BD2sXnvVeltrg%3D 17460705 (Pubitemid 47086775)
27. Mesa RA, Yao X, Cripe LD, et al.: Lenalidomide and prednisone for primary and post polycythemia vera/essential thrombocythemia myelofibrosis (MF): An Eastern Cooperative Oncology Group (ECOG) phase II trial [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 1753.
28. Quintas-Cardama A, Kantarjian HM, Thomas DA, et al.: Combined therapy with lenalidomide and prednisone renders durable clinical, histopathological, and molecular responses in patients with myelofibrosis [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 662.
29. EJ Baxter LM Scott PJ Campbell, et al. 2005 Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders Lancet 365 1054 1061 1:CAS:528:DC%2BD2MXisFGrs7g%3D 15781101
30. R Kralovics F Passamonti AS Buser, et al. 2005 A gain-of-function mutation of JAK2 in myeloproliferative disorders N Engl J Med 352 1779 1790 10.1056/NEJMoa051113 1:CAS:528:DC%2BD2MXjsFyhsLw%3D 15858187 (Pubitemid 40570926)
31. C James V Ugo JP Le Couedic, et al. 2005 A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera Nature 434 1144 1148 10.1038/nature03546 1:CAS:528:DC%2BD2MXjsF2ltbk%3D 15793561 (Pubitemid 40663494)
32. RL Levine M Wadleigh J Cools 2005 Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myelofibrosis with myeloid metaplasia Cancer Cell 7 387 397 10.1016/j.ccr.2005.03.023 1:CAS:528:DC%2BD2MXjvFSku7o%3D 15837627 (Pubitemid 40544655)
33. AD Pardanani RL Levine T Lasho, et al. 2006 MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients Blood 108 3472 3476 10.1182/blood-2006-04-018879 1:CAS:528:DC%2BD28Xht1ahsLzI 16868251 (Pubitemid 44776889)
34. F Delhommeau S Dupont 2009 Della Valle V, et al.: Mutation in TET2 in myeloid cancers N Engl J Med 360 2289 2301 10.1056/NEJMoa0810069 19474426
35. A Pardanani BL Fridley TL Lasho, et al. 2008 Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders Blood 111 2785 2789 10.1182/blood-2007-06-095703 1:CAS:528:DC%2BD1cXivFaktbc%3D 18006699
36. AV Jones A Chase RT Silver, et al. 2009 JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms Nat Genet 41 446 449 10.1038/ng.334 1:CAS:528:DC%2BD1MXjtFCis7c%3D 19287382
37. D Olcaydu A Harutyunyan R Jager, et al. 2009 A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms Nat Genet 41 450 454 10.1038/ng.341 1:CAS:528:DC%2BD1MXjtFCisb4%3D 19287385
38. GW Muller R Chen SY Huang, et al. 1999 Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production Bioorg Med Chem Lett 9 1625 1630 10.1016/S0960-894X(99)00250-4 1:CAS:528:DyaK1MXjvVKisbs%3D 10386948 (Pubitemid 29274209)
39. SA Schey P Fields JB Bartlett, et al. 2004 Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma J Clin Oncol 22 3269 3276 10.1200/JCO.2004.10.052 1:CAS:528: DC%2BD2cXpsVGrsLY%3D 15249589 (Pubitemid 41103682)
40. RA Mesa S Verstovsek C Rivera, et al. 2009 5-Azacitidine has limited therapeutic activity in myelofibrosis Leukemia 23 180 182 10.1038/leu.2008.136 1:CAS:528:DC%2BD1MXkvVeisQ%3D%3D 18509350
41. A Quintás-Cardama W Tong H Kantarjian, et al. 2008 A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis Leukemia 22 965 970 10.1038/leu.2008.91 18385750 (Pubitemid 351689878)
42. P Fenaux GJ Mufti E Hellstrom-Lindberg, et al. 2009 Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study Lancet Oncol 10 223 232 10.1016/S1470-2045(09)70003-8 1:CAS:528: DC%2BD1MXisFWjsbc%3D 19230772
43. • Verstovsek S, Kantarjian HM, Pardanani AD, et al.: The JAK inhibitor, INCB018424, demonstrates durable and marked clinical responses in primary myelofibrosis (PMF) and post-polycythemia/essential thrombocythemia myelofibrosis (post PV/ETMF) [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 1762. INCB018424 is the class-leading JAK2 inhibitor for myelofibrosis, with activity for splenomegaly and MF-associated symptoms.
44. Mesa RA, Verstovsek S, Kantarjian HM, et al.: INCB018424, a selective JAK1/2 inhibitor, significantly improves the compromised nutritional status and frank cachexia in patients with myelofibrosis (MF) [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 1760.
45. RA Mesa S Schwager D Radia, et al. 2009 The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis Leuk Res 33 1199 1203 10.1016/j.leukres.2009.01.035 19250674
46. • Pardanani AD, Gotlib J, Jamieson C, et al.: A phase I study of TG101348, an orally bioavailable JAK2-selective inhibitor, in patients with myelofibrosis [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 97. TG101348 is a promising selective JAK2 inhibitor with activity in MF.
47. • Shah NP, Olszynski P, Sokol L, et al.: A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis, post-polycythemia vera, or post-essential thrombocythemia myelofibrosis [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 98. This JAK2 inhibitor ceased development because of neurologic toxicity.
48. Verstovsek S, Tefferi A, Kornblau S, et al.: Phase II study of CEP701, an orally available JAK2 inhibitor, in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis [abstract]. Blood (ASH Annual Meeting Abstracts) 2007, 110:Abstract 3543.
49. Rambaldi A, Dellacasa CM, Salmoiraghi S, et al.: A phase 2A study of the histone-deacetylase inhibitor ITF2357 in patients with Jak2V617F positive chronic myeloproliferative neoplasms [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 100.
50. F Cervantes A Alvarez-Larran JC Hernandez-Boluda, et al. 2004 Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature Br J Haematol 127 399 403 10.1111/j.1365-2141.2004.05229.x 1:CAS:528:DC%2BD2cXhtVOms7jF 15521916 (Pubitemid 39536591)
51. A Manoharan WR Pitney 1984 Chemotherapy resolves symptoms and reverses marrow fibrosis in myelofibrosis Scand J Haematol 33 453 459 1:STN:280:DyaL2M%2FptVajsQ%3D%3D 6515328
52. Y Najean JD Rain 1997 Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group Blood 89 2319 2327 1:CAS:528:DyaK2sXitVyjtrs%3D 9116275
53. A Tefferi MN Silverstein CY Li 1997 2-Chlorodeoxyadenosine treatment after splenectomy in patients who have myelofibrosis with myeloid metaplasia Br J Haematol 99 352 357 10.1046/j.1365-2141.1997.3843198.x 1:CAS:528: DyaK2sXns1OhtLg%3D 9375753
54. G Barosi MA Elliot L Canepa, et al. 2002 Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies Leuk Lymphoma 43 2301 2307 10.1080/1042819021000040008 (Pubitemid 35386152)